Abstract
There is limited research into Invasive fungal disease (IFD) in children with no underlying disease. We undertook a retrospective study of children with IFD who did not suffer from another underlying disease, from June 2010 to March 2018 in Changsha, China. Nine children were identified. Eosinophil counts were elevated in six cases. The level of procalcitonin (PCT) was elevated in six cases. Fungal culture was positive in all patients, including eight cases of Cryptococcus neoformans and one case of Candida parapsilosis. 8.33 days following antifungal treatment, the body temperature of the eight patients affected by cryptococcal disease had returned to normal. Our study indicates that the primary pathogen in IFD was Cryptococcus neoformans in children who had no other underlying disease. Eosinophils can be considered to be indicators of cryptococcal infection. IFD in children with no other underlying disease has a satisfactory prognosis.
Highlights
There is limited research into Invasive fungal disease (IFD) in children with no underlying disease
We collected the clinical data from IFD children with no other underlying disease, between June 2010 and March 2018 in Changsha, China
18 patients fulfilled the criteria for IFD
Summary
There is limited research into Invasive fungal disease (IFD) in children with no underlying disease. Our study indicates that the primary pathogen in IFD was Cryptococcus neoformans in children who had no other underlying disease. Many factors have contributed to the emergence of IFD, including the HIV epidemic, organ transplantation, chronic disorders such as chronic lung diseases, immunosuppressive therapies, and the increase in the number of frequent hospitalizations and interventions. It has gradually emerged in the immunocompetent population. We collected the clinical data from IFD children with no other underlying disease, between June 2010 and March 2018 in Changsha, China.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
